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Clusterin expression in cutaneous
CD30-positive lymphoproliferative
disorders and their histologic simulants
Background: Clusterin is a ubiquitous 80 kDa heterodimeric
glycoprotein previously shown to be expressed on tumor cells of
systemic and, to a lesser extent, primary cutaneous anaplastic large cell
lymphoma (PC-ALCL). Lymphomatoid papulosis (LyP), an important
differential diagnosis of ALCL, has been studied for clusterin
expression in only a small number of cases. The aim of this study was
to compare clusterin immunostaining patterns in LyP and other
cutaneous histologic simulants with those of PC-ALCL.
Methods: Formalin-fixed, paraffin-embedded sections of PC-ALCL
(6), LyP (20), mycosis fungoides with large cell transformation
(MF-LCT, 12), pityriasis lichenoides et varioliformis acuta (PLEVA,
12), arthropod bite reaction (ABR, 12) and lymphomatoid reactions
(LR, 9) were immunostained for clusterin and evaluated for staining
pattern and distribution. All diagnoses were made with
clinicopathologic correlation.
Results: Characteristic dot-like Golgi staining was identified in 10/
20 LyP (50%), 4/6 PC-ALCL (67%) and 9/12 MF-LCT (75%). Two
of 12 PLEVA (17%), 1 of 12 ABR (8%) and 2 of 8 LR (25%) had
lymphocytes (, 25%) with diffuse cytoplasmic staining. Dermal
dendritic cells stained strongly for clusterin. High background staining
occurred in some cases.
Conclusion: Clusterin immunostaining does not reliably distinguish
between LyP, PC-ALCL or MF-LCT, but could distinguish LyP from
its reactive histologic simulants.
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Clusterin is a ubiquitous 80 kDa heterodimeric gly-
coprotein found in many tissues and in virtually all
body fluids, including plasma, urine, seminal fluid and
breast milk. The clusterin gene is located on human
chromosome 8 and is highly conserved across mam-
malian species.1,2 This protein is thought to play a role
in reproduction, lipid transport, apoptosis, cell sur-
vival and complement regulation; moreover, it has
been shown to be upregulated in areas of tissue
remodeling, in apoptotic disease states and in re-
sponse to injury.1
Wellman et al. identified clusterin as a specific
marker of systemic anaplastic large cell lymphoma
(S-ALCL) through hybridization of complementary
DNA to gene expression arrays followed by confir-
matory Western blot and immunohistochemical
studies. The authors proposed that the expression of
clusterin could be used diagnostically to distinguish
S-ALCL, the cells of which were positive in all 36
cases evaluated, from primary cutaneous ALCL (PC-
ALCL), whose cells were negative in all nine cases
studied. Obviously, this result has clinical importance
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because of differences in treatment and prognosis
between the two processes.3 Subsequent studies,
however, have shown that clusterin is expressed in
both S-ALCL and PC-ALCL, although to a lesser
extent in the latter.4,5
Clusterin expression in lymphomatoid papulosis
(LyP), an important differential diagnosis of ALCL in
the skin, has been reported in only a small number of
cases in the literature. Saffer et al. observed positive
clusterin staining in only one of seven cases of LyP.4
Similarly, clusterin expression in large cells of
mycosis fungoides with large cell transformation
(MF-LCT), another histologic mimic of ALCL, has
been evaluated in only a few cases in the literature.4,6
To our knowledge, clusterin expression has not been
described in other cutaneous lesions that resemble
LyP clinically and histologically, such as lymphoma-
toid reactions (LR) to drugs or other stimuli,
arthropod bite reactions (ABR) and pityriasis lichen-
oides et varioliformis acuta (PLEVA). The goal of this
study was to evaluate and compare clusterin
immunostaining patterns in LyP and the aforemen-
tioned cutaneous lymphoid lesions with those of PC-
ALCL.
Materials and methods
Following approval by the University of Michigan
Institutional Review Board, paraffin-embedded tissue
blocks and slides from 80 skin biopsies with histologic
diagnoses of LyP, ALCL,MF-LCT, ABR, PLEVA and
LRwere retrieved fromthe surgical pathology archives.
Following clinicopathologic review, the 80 cases were
classified as 6 ALCL, 20 LyP, 12 PLEVA, 12 ABR, 12
MF-LCTand 9 LR. Three of the six ALCL cases were
of PC type. The LRoccurred in response to a variety of
antigenic stimuli, including drugs (minocycline, ampi-
cillin, intravenous immunoglobulin, chemotherapy for
myeloid leukemia),7 tattoo pigment and treponemal
infection. A specific etiology was not established in
three cases. Nine cases were excluded from analysis
because of either lack of sufficient tissue (four cases) or
change in diagnosis after clinicopathologic review (five
cases), resulting in 71 cases for evaluation.
Formalin-fixed, paraffin-embedded tissue sections
were immunostained for clusterin. Briefly, deparaffi-
nized and rehydrated tissue sections, 4-mm thick, were
stained with a primary monoclonal antibody to
clusterin (1 : 200; Upstate Cell Signalling Solutions,
Lake Placid, NY, USA) following antigen retrieval
with 1 mmol/l ethylene-diamine-tetrasacetia acid
(EDTA) buffer (pH 8.0) in 95C water bath for 20 min.
Immunohistochemical staining was performed on
aDAKOAutostainer (DAKO,Carpinteria,CA,USA)
using DAKO LSAB1 and a 3,3#-diaminobenzidine
chromogen.
Immunostained sections from each case were
examined for a characteristic dot-like Golgi staining
pattern, as well asmembranous or diffuse cytoplasmic
staining patterns, by cells within the infiltrate,
especially the large atypical lymphoid cells. The
degree of positivity was recorded semiquantitatively
as percentage of infiltrating cells (, 1%, 1–25%, 25–
50% and . 50%) by each of the authors, includ-
ing two board-certified dermatopathologists (L. M.
and D. F.).
Results
The data for clusterin are shown in Table 1.
Characteristic dot-like perinuclear or Golgi staining
was identified in 4/6 PC-ALCL (67%), 10/20 LyP
(50%) and 9/12MF-LCT (75%).While 2/12 PLEVA
(17%), 1/12 ABR (8%) and 2/8 LR (25%) had clus-
terin staining in a small percentage of cells (, 25%),
the staining pattern was diffuse and cytoplasmic
without Golgi accentuation, which differed from LyP,
PC-ALCL and MF-LCT. With respect to the LyP
cases, 8 of 15 type A lesions, 0 of 1 type B lesion and 2
of 4 type C lesions showed clusterin expression. The
majority of cases contained only small percentages
(, 25%) of cells staining positive for clusterin. How-
ever, higher percentages of positive cells were noted in
two cases of ALCL (25–50%, 1 and 50–75%, 1), two
cases of LyP (25–50%) and four cases of MF-LCT
(25–50%, 3 and 50–75%, 1) (Fig. 1).
A subset of dermal dendritic cells within the
lymphoid infiltrates showed intense and diffuse
cytoplasmic staining for clusterin in many cases
(Fig. 2). While these dendritic cells with clusterin
expression were observed in each of the diagnoses
included in this study, they were more prominent in
MF-LCT (11/12) and LR (7/9) compared with LyP
(8/20), ALCL (2/6) and ABR (6/12). In a parallel
study, we evaluated 12 cases of Langerhans cell
histiocytosis (LCH) and found that 3 cases (25%)
showed focal and weak cytoplasmic staining for
clusterin (data not shown).
Table 1. Data on clusterin expression in CD30-positive lymphoprolifer-
ative disorders and histologic simulants
Diagnosis Cases (n)
Score
, 1 1–25% 25–50% 50–75%
ALCL 6 2 2 1 1
LyP 20 10 8 2 0
MF-LCT 12 3 5 3 1
PLEVA 12 10 2 0 0
ABR 12 11 1 0 0
LR 9 6 3 0 0
Total 71 42 21 6 2
ABR, arthropod bite reaction; ALCL, anaplastic large cell lymphoma; LR,
lymphomatoid reactions; LyP, lymphomatoid papulosis; MF-LCT, mycosis
fungoides with large cell transformation; PLEVA, pityriasis lichenoides et
varioliformis acuta.
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High background staining for clusterin occurred in
a significant number of cases and was especially
prominent in areas of ulceration, hemorrhage or
tissue necrosis (Fig. 3). In some cases, the extent of
background staining hindered the evaluation of the
staining patterns within the lymphoid infiltrates.
Discussion
LyP and PC-ALCL comprise a spectrum of CD30-
positive lymphoproliferative disorders of the skin.
These disorders are considered low-grade malignan-
cies characterized by lesions that have a tendency to
spontaneously regress and a relatively indolent cli-
nical course with an overall favorable prognosis.8–10
These lymphoproliferative processes may share his-
tologic and immunophenotypic features,making their
distinction problematic.9,11 LyP and ALCL have
variable numbers of large CD30-positive lymphoid
cells with anaplastic cytomorphology.9,12 The type C
variant of LyP has a predominance of CD30-positive
cells and may be histologically indistinguishable from
PC-ALCL. This pattern can also be seen in S-ALCL
secondarily involving the skin and in MF-LCT.
Both disorders are important to distinguish from
LyP and PC-ALCL because of the more aggressive
clinical course in the former two entities.13–15 Type A
(histiocytic) LyP contains similar CD30-positive
tumor cells, but these large cells are admixed with
Fig. 2. Clusterin immunostaining of dendritic cells is seen in
a lymphomatoid drug reaction.
Fig. 1. Clusterin immunostaining with
a Golgi pattern in various CD30-positive
lymphoproliferative disorders and reactive
conditions: (A) lymphomatoid papulosis with
, 25% of lesional cells staining. B) Primary
cutaneous anaplastic large cell lymphoma
(PC-ALCL) with 25–50% of lesional cells
positive for clusterin. C) PC-ALCL with 50–
75% of lesional cells expressing clusterin. D)
Lymphomatoid reaction with a low percent-
age of clusterin-positive cells with diffuse
cytoplasmic staining (arrowheads); note also
the presence of clusterin-positive dendritic
cells and non-specific background staining.
Fig. 3. Background staining of clusterin is present in association




other inflammatory cells like neutrophils, eosinophils
and histiocytes in the dermis.9,11 Thus, the differential
diagnosis of type A LyP includes a variety of reactive
conditions in the skin, namely PLEVA, ABR and
some LR.16 Similar to type A LyP, these reactive
processes may also contain some CD30-positive large
lymphoid cells that intermingle with other inflamma-
tory cells.7,9,17 Thus, it would be useful to identify an
immunohistochemical marker that could distinguish
ALCL fromLyPor LyP from its histologic mimickers.
Wellman et al. initially identified clusterin in cases
of S-ALCL but not in any cases of PC-ALCL.3
Subsequent studies refuted this finding by showing
clusterin staining in both types of ALCL, although the
data were somewhat variable.4–6 In two of these
studies, fewer PC-ALCL lesions (41–56%) were
positive compared with S-ALCL secondarily involv-
ing the skin (75%) and S-ALCL occurring at
extracutaneous sites (82–95%).4,5 One study reported
clusterin expression in all cases of ALCL regardless of
whether the process was cutaneous or systemic.6 A
perinuclear dot-like Golgi staining pattern, with or
without diffuse cytoplasmic or membranous pattern,
within the cytoplasm of large atypical lymphoid cells
had previously been reported to be characteristic of
ALCL.3,6 However, some of these studies have also
included cells with diffuse cytoplasmic or membra-
nous staining but without Golgi staining as positive in
their results. In the prior studies, clusterin staining
patterns or proportions of positive cells were not
described in (1/7) LyP or (1/2) MF-LCT cases.4,6
Clusterin expression has not been studied in the
reactive cutaneous processes that may simulate LyP
clinically and histologically and that may contain
CD30-positive large lymphoid cells.
The presence of clusterin expression in 67% of
cutaneous ALCL in our study and the presence of low
percentages of positive cells within the infiltrate
(, 25% in most cases) are consistent with previous
published data.4,5 In contrast to Nascimento et al.,
who reported clusterin staining in all of their
cutaneous ALCL cases, the other previous studies
found lower positivity in number of cases and
proportions of positive cells in cutaneous relative to
nodal or secondary cutaneous ALCL.4–6 The reason
for the disparity in staining results between the
different studies is not entirely clear but probably is
multifactorial. The staining results may have been
influenced by the immunohistochemical method
used. A few of the previous studies used similar
heat-induced antigen retrieval in citrate buffer at pH
6.0 prior to clusterin staining. Like Lae et al., we found
in preliminary results that pretreatment with EDTA
pH 8.0 resulted in a crisper staining pattern and less
background staining when compared with the citrate
buffer method. Nevertheless, we noted high back-
ground staining in a subset of our cases, particularly
when ulceration, hemorrhage or tissue necrosis was
prominent. This finding can be explained by the
presence of clusterin in normal serum and its ex-
travasation into areas of tissue injury. Moreover, it is
possible that clusterin expression is upregulated in
lymphoid cells and/or dermal dendritic cells and/or
excreted extracellularly in response to inflammatory
mediators at the site of tissue injury. Regardless of
the cause, this non-specific background staining can
certainly hinder the interpretation of specific stain-
ing. We speculate that the stromal collagen and/or
dendritic cells of the dermal milieu could down-
regulate clusterin expression in lymphoid cells when
compared with extracutaneous lesions, although
this hypothesis would not explain the findings by
Nascimento et al.
Contrary to the previous study that evaluated
clusterin expression in LyP, we found a substantially
higher percentage of positive cases (50%), similar to
our results for ALCL. With the exception of two LyP
cases, which had up to 50% of lesional cells staining
for clusterin, the remainder of the positive cases of LyP
had a low percentage (, 25%) of clusterin-positive
cells. Fifteen of our LyP cases were the most common
type (type A), whereas four were type C (ALCL like)
and one was type B (MF like). Ten of our LyP cases
were positive for clusterin, including 8 of 15 (53%)
typeA lesions and 2 of 4 (50%) typeC lesions; onlyone
type B lesion was included in our study and was
negative. The difference between our staining results
in LyP and those of Saffer et al. could be explained by
the difference in the type of LyP cases included,
variability in tissue fixation of cases and the number of
cases evaluated.4 Our study included all three types of
LyP lesions, whereas the types of LyP lesions studied
by Saffer et al. were not specified. We evaluated cases
that were obtained within our institution, as opposed
to Saffer et al. who stated that their cases included
internal and referral cases that may have had sig-
nificant differences in tissue fixation.
Previous data onMF-LCTare difficult to interpret
because of the exceedingly low number of cases
examined for clusterin expression.4,6 The majority of
cases (75%) in our study were positive and most
showed a low percentage of clusterin-positive cells;
however, four cases of MF-LCT had between 25%
and 75% of clusterin-positive cells. Nascimento et al.
found the dot-like Golgi pattern to be specific for
either primary or secondary ALCL. This Golgi
pattern, however, was very prominent in our cases
of MF-LCT. These findings highlight the non-specific
nature of clusterin expression and, because of the
differences in prognosis of these lesions, raise doubts
about its clinical utility.
Clusterin expression was also found in a small
subset of reactive conditions that included PLEVA,
ABR and LR to various antigenic stimuli, such as
Clusterin and CD30+ lymphoproliferative disorders
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drugs, tattoo pigment and infectious agents. A smaller
percentage of these lesions were positive for clusterin
when compared with LyP lesions, only a low
percentage (, 25%) of lesional cells were positive in
each category, and the staining pattern of positive cells
in the infiltrate was diffuse and cytoplasmic, which
differed from the perinuclear dot-like Golgi pattern of
staining in LyP. Thus, this disparity in staining pattern
was useful in distinguishing these reactive cutaneous
infiltrates from LyP.
Intense, diffuse cytoplasmic staining of clusterin has
been consistently noted in follicular dendritic cells of
lymph nodes and fibroblastic reticular cells in lymph
nodes and bonemarrow.3–6 In fact, clusterin has been
shown to be a highly specific marker for follicular
dendritic cell sarcoma.18 However, the authors in that
study did not specifically evaluate clusterin expression
in dermal dendritic cells, which we found to have
a dense and diffuse cytoplasmic staining pattern
similar to that described for follicular dendritic and
fibroblastic reticular cells. These clusterin-positive
dendritic cells were most prominent in LR and,
curiously, inMF-LCT. In a parallel studyof 12 cases of
LCH involving the skin, Langerhans cells lacked the
strong diffuse clusterin positivity that was seen in the
dendritic cells of some of our cases, with only 3 (25%)
cases showing weak and focal positive staining. In
a study comparing follicular dendritic cell tumor to
other dendritic cell tumors, Grogg et al. reported
a higher percentage (8/14, 57%) of LCH lesions
positive for clusterin, some with a moderate degree of
staining.19 However, the authors do not specify the
anatomic location of their LCH lesions. Our results
suggest that the clusterin-positive dermal dendritic
cells in our cases are probably not Langerhans cells.
However, we did not perform additional studies, such
as double-labeling immunohistochemistry, in an
attempt to further delineate the immunophenotype
of these clusterin-positive dendritic cells.
In summary, clusterin expression is observed in the
large atypical lymphoid cells occurring in the
spectrum of CD30-positive lymphoproliferative dis-
orders, as well as in MF-LCT, involving the skin and
cannot be used reliably to distinguish among these
entities. Clusterin also is expressed on a small subset of
inflammatory cells within the infiltrate of some cases
of PLEVA, ABR and LR, albeit in a lower percentage
of cases and in a diffuse cytoplasmic pattern rather
than theGolgi pattern seen in the large lymphoid cells
of LyP. This difference in staining pattern could
discriminate between these reactive processes and
type A LyP, although only a small number and limited
types of LR were included. We did not attempt to
distinguish between S-ALCL and PC-ALCL because
this has been done in prior studies. Clusterin exhibits
high background staining, particularly in areas of
ulceration, necrosis and hemorrhage, in some cases,
which limits its diagnostic usefulness in dermatopa-
thology. Clusterin also intensely labels a subset of
dermal dendritic cells within malignant and reactive
lymphoid infiltrates of the skin in some cases. Further
studies may shed light on the role of clusterin in the
dermal dendritic microenvironment.
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